STAR 11282

Avavilable at 1 location

SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

STAR 18013

Avavilable at 1 location

SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

USOR 16065

Avavilable at 7 locations

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205)

USO 20133

Avavilable at 9 locations

MOR208C310: A Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

STAR 16213

Avavilable at 1 location

(UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

STAR 18263

Avavilable at 1 location

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology